For years, Africa relied on medicines shipped from halfway across the world to keep people alive with HIV. Antiretroviral drugs - the life-saving pills that stop the virus from multiplying - were mostly made in India or Europe. The cost was high, supply chains were fragile, and delays could mean lives lost. But something major changed in 2025. For the first time ever, the Global Fund an international financing organization that supports programs to fight AIDS, tuberculosis, and malaria bought HIV treatment made in Africa. Not just a few bottles. Not a test run. Enough to treat over 72,000 people every year. The medicine? TLD - a single pill combining tenofovir, lamivudine, and dolutegravir. And it came from a factory in Kenya.
Why African-Made ARVs Matter
Sub-Saharan Africa carries 65% of the world’s HIV cases. Yet it produces less than 3% of its own medicines. That imbalance isn’t just unfair - it’s dangerous. When global supply chains broke down during the pandemic, African countries scrambled for pills. Some ran out. Others waited months. The cost of importing drugs isn’t just financial. It’s time. It’s trust. It’s control.
Now, with African manufacturers like Universal Corporation Ltd a Kenyan pharmaceutical company that became the first African manufacturer to receive WHO prequalification for TLD in 2023 producing WHO-prequalified antiretroviral drugs, the continent is taking charge. WHO prequalification isn’t a stamp of approval - it’s a global gold standard. It means the medicine meets the same safety, quality, and effectiveness benchmarks as those made in the U.S. or Europe. No compromises.
Before this shift, most African countries got their ARVs from Indian generics. Those helped cut the price of treatment from $10,000 per person per year in 2000 to under $100 by 2015. But relying on one region created new risks. Geopolitical tensions, shipping delays, currency fluctuations - all could cut off supply. Local production changes that. When a country can make its own pills, it doesn’t have to beg for them.
The TLD Breakthrough
TLD is the current gold standard for first-line HIV treatment in low-resource settings. It’s simple - one pill, once a day. It’s powerful - it suppresses the virus more reliably than older regimens. And it’s forgiving - even if someone misses a dose now and then, it still works. That’s huge in places where clinics are far away, transport is unreliable, and stigma makes it hard to pick up pills regularly.
The fact that Universal Corporation Ltd in Kenya got WHO prequalification for TLD in 2023 was a turning point. It proved African manufacturers could meet international standards. Then, on May 6, 2025, the Global Fund shipped its first batch of African-made TLD to Mozambique. That wasn’t just a delivery. It was a signal. To manufacturers, donors, governments - and to the 25 million people living with HIV in Africa - that this is real. This isn’t a pilot. This is the new normal.
Dr. Ussene Hilário Isse, Mozambique’s Minister of Health, put it plainly: “Africa’s growing capacity to locally produce lifesaving medications marks a strategic shift for our continent.”
Beyond Pills: Building the Whole System
Getting pills to people isn’t just about manufacturing. It’s about diagnostics, supply chains, and trained health workers. And that’s where other breakthroughs are happening.
In Nigeria, Codix Bio a Nigerian in-vitro diagnostics company that received a sublicense from SD Biosensor to manufacture HIV rapid diagnostic tests is now producing HIV rapid tests under a technology transfer agreement with WHO and the Medicines Patent Pool. These aren’t just tests. They’re tools for early detection. For knowing who needs treatment. For tracking whether treatment is working. Before, many clinics had to wait weeks for lab results. Now, they can test and start treatment in one visit.
South Africa made headlines in October 2025 when it became the first African country to register the twice-yearly HIV injection, cabotegravir long-acting (CAB LA). That’s right - a shot every six months instead of a daily pill. And it’s not just the brand version. Gilead Sciences licensed six African manufacturers to produce generic versions. Experts say prices could drop 80-90% below the brand cost once generics hit the market. That’s game-changing for rural areas where clinic visits are hard.
Even more, Gilead is giving away lenacapavir - a new, ultra-long-acting PrEP drug - at no profit until generics can take over. They’re working with PEPFAR and the Global Fund to get it into 18 high-burden countries by the end of 2025. This isn’t charity. It’s a bridge. A way to get cutting-edge prevention tools to people now, while local manufacturers build capacity to make them later.
The Numbers Don’t Lie
In 2010, 1.3 million people died from AIDS-related causes. In 2022, that number dropped to 630,000. Why? Because more people got treatment. In Eastern and Southern Africa, 93% of people with HIV now know their status. 83% are on treatment. 78% have the virus under control. That’s progress. But in Western and Central Africa, the numbers are lower: 81%-76%-70%. Why the gap? Because access isn’t equal. And until local production scales up, it won’t be.
Africa needs about 15 million person-years of first-line ARV treatment every year. Right now, African manufacturers are only supplying a fraction of that. But the pipeline is filling fast. New factories are set to open in Q4 2025. Funding from Unitaid, the Gates Foundation, and CIFF is helping them get there. The African Union’s Pharmaceutical Manufacturing Plan aims to raise local production from 2-3% to 40% by 2040. That’s ambitious. But with the right support, it’s possible.
What’s Still Holding Us Back?
Progress is real. But challenges remain. One big one? Regulatory fragmentation. Every country has its own rules. What’s approved in Kenya might not be accepted in Nigeria. Harmonizing regulations across borders would cut costs and speed up access. Another? Financing. Building a pharmaceutical plant costs hundreds of millions. Most African governments can’t fund it alone. International partnerships are essential - but they must be long-term. Not just one-time grants.
There’s also the need for African-led research. Too often, treatments are designed for Western populations. But African patients have different co-infections, genetic profiles, and lifestyles. Local drug development isn’t just about making pills - it’s about making the right pills.
And then there’s integration. HIV services still operate in silos. A person might get their ARVs at one clinic, their TB test at another, their mental health care at a third. Connecting these services saves money, reduces stigma, and improves outcomes. The African Radical Agenda for HIV Sustainability calls this “moving from silos to integrated governance.” It’s not just smart. It’s necessary.
The Road Ahead
By 2030, African-made antiretrovirals could supply 20-30% of the continent’s needs. That’s not enough to cover everyone - but it’s enough to break the cycle of dependence. It’s enough to prove that Africa doesn’t need to wait for others to act. It can lead.
The Global Fund’s decision to buy TLD from Kenya wasn’t an act of charity. It was a market-shaping move. It told manufacturers: “We will buy from you. We will pay fairly. We will trust you.” That’s powerful. It creates jobs. It builds expertise. It turns patients into producers.
When a mother in rural Malawi gets her HIV pills from a factory just a few hours away, she doesn’t just get medicine. She gets dignity. Security. A future. And that’s what this is really about - not just pills, but power.
Write a comment